Fmr LLC Has $602,000 Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)

Fmr LLC increased its position in Nkarta, Inc. (NASDAQ:NKTX) by 97.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 133,149 shares of the company’s stock after buying an additional 65,600 shares during the quarter. Fmr LLC’s holdings in Nkarta were worth $602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Meeder Asset Management Inc. bought a new position in shares of Nkarta during the second quarter valued at $26,000. GAMMA Investing LLC grew its position in shares of Nkarta by 110.9% in the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after buying an additional 5,243 shares during the last quarter. Forefront Analytics LLC bought a new stake in shares of Nkarta in the 2nd quarter valued at about $70,000. Intech Investment Management LLC acquired a new position in shares of Nkarta in the third quarter worth approximately $74,000. Finally, SG Americas Securities LLC bought a new stake in Nkarta in the third quarter valued at approximately $93,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Stock Down 4.4 %

Shares of NKTX opened at $2.17 on Thursday. Nkarta, Inc. has a 12-month low of $2.13 and a 12-month high of $16.24. The stock has a market cap of $153.14 million, a P/E ratio of -1.15 and a beta of 0.82. The business’s fifty day moving average is $3.07 and its 200 day moving average is $4.74.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NKTX shares. Rodman & Renshaw assumed coverage on shares of Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective for the company. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. HC Wainwright dropped their price target on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Needham & Company LLC reduced their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 8th. Finally, Mizuho decreased their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $15.00.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.